Cargando…
A Panel of Plasma Biomarkers for Differential Diagnosis of Parkinsonian Syndromes
OBJECTIVE: The aim of our study is to explore the most reliable panel of plasma biomarkers for differential diagnosis of parkinsonian syndromes (PDSs). We selected five kinds of neurodegenerative proteins in plasma: neurofilament light chain (NfL), α-synuclein (α-syn), total tau, β-amyloid 42 (Aβ42)...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8891509/ https://www.ncbi.nlm.nih.gov/pubmed/35250451 http://dx.doi.org/10.3389/fnins.2022.805953 |
_version_ | 1784661898878255104 |
---|---|
author | Li, Qi Li, Zhen Han, Xiaoxuan Shen, Xiao Wang, Fei Bai, Lipeng Li, Zhuo Zhang, Rui Wang, Yanlin Zhu, Xiaodong |
author_facet | Li, Qi Li, Zhen Han, Xiaoxuan Shen, Xiao Wang, Fei Bai, Lipeng Li, Zhuo Zhang, Rui Wang, Yanlin Zhu, Xiaodong |
author_sort | Li, Qi |
collection | PubMed |
description | OBJECTIVE: The aim of our study is to explore the most reliable panel of plasma biomarkers for differential diagnosis of parkinsonian syndromes (PDSs). We selected five kinds of neurodegenerative proteins in plasma: neurofilament light chain (NfL), α-synuclein (α-syn), total tau, β-amyloid 42 (Aβ42) and β-amyloid 40 (Aβ40), and investigated the diagnostic value of these biomarkers. METHODS: A total of 99 plasma samples from patients with Parkinson’s disease (PD), multiple system atrophy (MSA), progressive supranuclear palsy, and age-matched healthy controls (HCs) were enrolled in our study. Plasma NfL, α-syn, total tau, Aβ42, and Aβ40 levels were quantified by ultrasensitive single molecule array immunoassay. We used logistic regression analyses to examine diagnostic accuracy of these plasma biomarkers. Disease severity was assessed by the modified Hoehn and Yahr staging scale, Unified Parkinson’s Disease Rating Scale part III (UPDRS III), and the Mini-Mental State Examination (MMSE), and subsequently, correlation analysis was performed. RESULTS: A combination of α-syn, Aβ42, Aβ40, Aβ42/40, and NfL could achieve a best diagnostic value in differentiating PDSs from HC and PD from HC, with an AUC of 0.983 and 0.977, respectively. By adding NfL to measurements of α-syn or Aβ42 or Aβ40 or Aβ42/40, the best discriminating panel was formed in differentiating atypical parkinsonian disorder (APD) and HC, and the discriminatory potential could reach a sensitivity of 100% and specificity of 100% (AUC = 1.000). For further distinguishing PD from APD, we found a combination of NfL, Aβ42, and total tau was the most reliable panel with equally high diagnostic accuracy. With respect to differentiating the subtypes of APD from one another, our results revealed that measurement of NfL, total tau, Aβ42, Aβ40, and Aβ42/40 was the best discriminating panel. Correlation analysis suggests that plasma Aβ42 levels were positively correlated to UPDRS part III scores in MSA. In terms of cognitive function, there was a relationship between plasma Aβ42/40 level and MMSE scores in patients with APD. CONCLUSION: In our study, various combinations of plasma biomarkers have great potentialities in identifying PDSs, with important clinical utility in improving diagnostic accuracy. Plasma NfL may have added value to a blood-based biomarker panel for differentiating PDSs. |
format | Online Article Text |
id | pubmed-8891509 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88915092022-03-04 A Panel of Plasma Biomarkers for Differential Diagnosis of Parkinsonian Syndromes Li, Qi Li, Zhen Han, Xiaoxuan Shen, Xiao Wang, Fei Bai, Lipeng Li, Zhuo Zhang, Rui Wang, Yanlin Zhu, Xiaodong Front Neurosci Neuroscience OBJECTIVE: The aim of our study is to explore the most reliable panel of plasma biomarkers for differential diagnosis of parkinsonian syndromes (PDSs). We selected five kinds of neurodegenerative proteins in plasma: neurofilament light chain (NfL), α-synuclein (α-syn), total tau, β-amyloid 42 (Aβ42) and β-amyloid 40 (Aβ40), and investigated the diagnostic value of these biomarkers. METHODS: A total of 99 plasma samples from patients with Parkinson’s disease (PD), multiple system atrophy (MSA), progressive supranuclear palsy, and age-matched healthy controls (HCs) were enrolled in our study. Plasma NfL, α-syn, total tau, Aβ42, and Aβ40 levels were quantified by ultrasensitive single molecule array immunoassay. We used logistic regression analyses to examine diagnostic accuracy of these plasma biomarkers. Disease severity was assessed by the modified Hoehn and Yahr staging scale, Unified Parkinson’s Disease Rating Scale part III (UPDRS III), and the Mini-Mental State Examination (MMSE), and subsequently, correlation analysis was performed. RESULTS: A combination of α-syn, Aβ42, Aβ40, Aβ42/40, and NfL could achieve a best diagnostic value in differentiating PDSs from HC and PD from HC, with an AUC of 0.983 and 0.977, respectively. By adding NfL to measurements of α-syn or Aβ42 or Aβ40 or Aβ42/40, the best discriminating panel was formed in differentiating atypical parkinsonian disorder (APD) and HC, and the discriminatory potential could reach a sensitivity of 100% and specificity of 100% (AUC = 1.000). For further distinguishing PD from APD, we found a combination of NfL, Aβ42, and total tau was the most reliable panel with equally high diagnostic accuracy. With respect to differentiating the subtypes of APD from one another, our results revealed that measurement of NfL, total tau, Aβ42, Aβ40, and Aβ42/40 was the best discriminating panel. Correlation analysis suggests that plasma Aβ42 levels were positively correlated to UPDRS part III scores in MSA. In terms of cognitive function, there was a relationship between plasma Aβ42/40 level and MMSE scores in patients with APD. CONCLUSION: In our study, various combinations of plasma biomarkers have great potentialities in identifying PDSs, with important clinical utility in improving diagnostic accuracy. Plasma NfL may have added value to a blood-based biomarker panel for differentiating PDSs. Frontiers Media S.A. 2022-02-17 /pmc/articles/PMC8891509/ /pubmed/35250451 http://dx.doi.org/10.3389/fnins.2022.805953 Text en Copyright © 2022 Li, Li, Han, Shen, Wang, Bai, Li, Zhang, Wang and Zhu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neuroscience Li, Qi Li, Zhen Han, Xiaoxuan Shen, Xiao Wang, Fei Bai, Lipeng Li, Zhuo Zhang, Rui Wang, Yanlin Zhu, Xiaodong A Panel of Plasma Biomarkers for Differential Diagnosis of Parkinsonian Syndromes |
title | A Panel of Plasma Biomarkers for Differential Diagnosis of Parkinsonian Syndromes |
title_full | A Panel of Plasma Biomarkers for Differential Diagnosis of Parkinsonian Syndromes |
title_fullStr | A Panel of Plasma Biomarkers for Differential Diagnosis of Parkinsonian Syndromes |
title_full_unstemmed | A Panel of Plasma Biomarkers for Differential Diagnosis of Parkinsonian Syndromes |
title_short | A Panel of Plasma Biomarkers for Differential Diagnosis of Parkinsonian Syndromes |
title_sort | panel of plasma biomarkers for differential diagnosis of parkinsonian syndromes |
topic | Neuroscience |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8891509/ https://www.ncbi.nlm.nih.gov/pubmed/35250451 http://dx.doi.org/10.3389/fnins.2022.805953 |
work_keys_str_mv | AT liqi apanelofplasmabiomarkersfordifferentialdiagnosisofparkinsoniansyndromes AT lizhen apanelofplasmabiomarkersfordifferentialdiagnosisofparkinsoniansyndromes AT hanxiaoxuan apanelofplasmabiomarkersfordifferentialdiagnosisofparkinsoniansyndromes AT shenxiao apanelofplasmabiomarkersfordifferentialdiagnosisofparkinsoniansyndromes AT wangfei apanelofplasmabiomarkersfordifferentialdiagnosisofparkinsoniansyndromes AT bailipeng apanelofplasmabiomarkersfordifferentialdiagnosisofparkinsoniansyndromes AT lizhuo apanelofplasmabiomarkersfordifferentialdiagnosisofparkinsoniansyndromes AT zhangrui apanelofplasmabiomarkersfordifferentialdiagnosisofparkinsoniansyndromes AT wangyanlin apanelofplasmabiomarkersfordifferentialdiagnosisofparkinsoniansyndromes AT zhuxiaodong apanelofplasmabiomarkersfordifferentialdiagnosisofparkinsoniansyndromes AT liqi panelofplasmabiomarkersfordifferentialdiagnosisofparkinsoniansyndromes AT lizhen panelofplasmabiomarkersfordifferentialdiagnosisofparkinsoniansyndromes AT hanxiaoxuan panelofplasmabiomarkersfordifferentialdiagnosisofparkinsoniansyndromes AT shenxiao panelofplasmabiomarkersfordifferentialdiagnosisofparkinsoniansyndromes AT wangfei panelofplasmabiomarkersfordifferentialdiagnosisofparkinsoniansyndromes AT bailipeng panelofplasmabiomarkersfordifferentialdiagnosisofparkinsoniansyndromes AT lizhuo panelofplasmabiomarkersfordifferentialdiagnosisofparkinsoniansyndromes AT zhangrui panelofplasmabiomarkersfordifferentialdiagnosisofparkinsoniansyndromes AT wangyanlin panelofplasmabiomarkersfordifferentialdiagnosisofparkinsoniansyndromes AT zhuxiaodong panelofplasmabiomarkersfordifferentialdiagnosisofparkinsoniansyndromes |